The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)

A Clinical Study to Evaluate the Efficacy and Safety of MK0633 in Patients With Atherosclerosis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00421278

Enrollment

180

Registered

2007-01-11

Start date

2006-11-30

Completion date

2007-01-31

Last updated

2016-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Brief summary

A study to test the effects of study drug (MK 0633) on patients with Atherosclerotic disease

Interventions

Single dose MK0633 100mg po in the fed state administered during a 4-wk study.

Sponsors

Merck Sharp & Dohme LLC

Lead SponsorINDUSTRY

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

40 Years to 85 Years

Healthy volunteers

No

Inclusion criteria

* Patients with plaque in coronary or leg arteries, known as atherosclerosis or peripheral vascular disease * Inflammatory marker found in your blood, known as hsCRP \> 0.5 mg/L

Exclusion criteria

* Age \< 40 or \> 85 * Female * Heart attack, coronary artery bypass, stroke or unstable angina in last 3 months * Liver diseased or abnormalities * HIV infection * Lupus, rheumatoid arthritis, cancer \<5 years

Design outcomes

Primary

Measure	Time frame
To evaluate the effects of the drug, MK 0633, on an inflammatory marker in your blood that may affect the plaque in the arteries, know as atherosclerosis	4 Weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026